A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant Academic Article uri icon

abstract

  • Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses.Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals.The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission.This method was feasible and safe but was minimally immunogenic.

authors

  • Davis, Ian D
  • Quirk, Juliet
  • Morris, Leone
  • Seddon, Lauren
  • Tai, Tsin Yee
  • Whitty, Genevieve
  • Cavicchiolo, Tina
  • Ebert, Lisa
  • Jackson, Heather
  • Browning, Judy
  • MacGregor, Duncan
  • Wittke, Frederick
  • Winkels, Gregor
  • Alex, Regina
  • Miloradovic, Lena
  • Maraskovsky, Eugene
  • Chen, Weisan
  • Cebon, Jonathan

publication date

  • 2017

has subject area